Immunomodulators Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Immunomodulators Market
The immunomodulators market size was valued at USD 161.57 billion in 2019, and the market is now projected to grow from USD 186.12 billion in 2020 to USD 44.94 billion by 2027, exhibiting a CAGR of 6.3% during the forecast period of 2020-2027.
The COVID-19 pandemic has dynamically contributed to the global immunomodulators market by an increase in the sale of the products in terms of emergency. Many pharma companies during timand this pandemic have been very keen in making sure that the supply chain breaks not to interfere with their level of sales. These companies have advanced their supply chain and purchasing resources, the effectiveness of their Company’s R&D have also been augmented and the funds dedicated to Company’s manufacturing management and quality assurance has also been raised as well. This led to the boost of immunomodulators market growth.
Multiple sclerosis that has recently increased throughout the world is considered as the second leading cause of death with a reference to cardiovascular diseases. For instance, there is a growing number of Clincal trials for new immunotherapeutic agents ponesimod, ozanimod, and laquinimod that are used in treatment of multiple sclerosis and other immunological disorders; these are factors that will fuel the immunomodulators market share.
Cancer is rated among the leading causes of death as we speak and today’s research entails identification of new ways of enhancing the management of this disease. Over recent years, numerous clinical trials have shown that immunomodulatory therapy helps to control cancer disease. White and black blood cells are active in the formation of tumours thus organizations are directing massive capital on immunotherapy and targeted medicine for early diagnosis.
Comprehensive Analysis of Immunomodulators Market
The immunomodulators market is responding quite an unprecedented rate of growth because of its market segmentation. This indicators growth in different regions by substituting the major forces of supply and demand which define the shape of local pharmacy benefit management market. Therefore, they are logically divided into 2 Segments, By Product Type Analysis and By Application Analysis. Depending on the product type, the market segment comprises immunosuppressive agents and immunostimulatory agents. The immunosuppressants segment further comprises of antimetabolites; calcineurin inhibitors; glucocorticoids; and others. In addition, the Immunostimulants segment is further divided into vaccines, antibodies, and other products. When it comes to application, the cancer, respiratory disorders, HIV/AIDS, and others owns the market. The other segment, which consists of rheumatoid arthritis, multiple sclerosis, Crohn’s disease and others, has the largest market share globally because these products are commonly used for treatment of these diseases. This together with new drug development activities for unmet needs and expected products for several indications are expected to present future growth prospect.
The market size in North America stood at USD 61.91 billion in 2019. The dominance of this region can be explained by the increasing rate of diseases affecting the U.S population. Secondly, another confusing influential cause of the growth of the area is presence of main contestants, together with introduction of fresh products. Europe stands second to Asia because of its spending in research and development of potent medicines and treatments.
The significant players in the pharmaceutical market are F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Biogen (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Amgen, Inc (U.S.), Bristol-Myers & Squibb Company (U.S.), Merck Sharp & Dohme Corp. (U.S.) and Eli Lilly and Company (U.S.). They are the key player that ensures the industry's success while still having to keep pace with their innovation in product and services. They offer a competitive zone that incites the growth of technologies and quality assurance. They operate on a global scale and have a wide range of product lines ensuring that the market players compete on a fair playing field bringing in innovations that result in the market's evolution.
In July 2021, Prograf has been authorized for use in combination with other immunosuppressive drugs to lower the risk of graft rejection in adult and pediatric lung transplant patients. First, Prograf was available by permit only for the therapy of organ rejection in patients who underwent liver transplantation; later the range of activities regarding the permit expanded and Prograf is now allowed to be used in kidney and heart transplant patients.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2016-2027
Base Year 2019
Forecast Period 2020-2027
Historical Period 2016-2018
Unit Value (USD Billion)
Segmentation Product Type; Application; and Region
By Product Type
Immunosuppressants
Immunostimulants
By Application
Respiratory
Oncology Multiple Sclerosis
Others
By Geography
North America
By Product Type
By Application
By Country
USA (By Product Type)
Canada (By Product Type)
Europe
By Product Type
By Application
By Country
UK (By Product Type)
Germany (By Product Type)
France (By Product Type)
Italy (By Product Type)
Spain (By Product Type)
Scandinavia (By Product Type)
Rest of Europe (By Product Type)
Asia Pacific
By Product Type
By Application
By Country
Japan (By Product Type)
China (By Product Type)
Australia (By Product Type)
India (By Product Type)
Southeast Asia (By Product Type)
Rest of Asia Pacific (By Product Type)
Latin America
By Product Type
By Application
By Country
Brazil (By Product Type)
Mexico (By Product Type)
Rest of Latin America (By Product Type)
The Middle East & Africa
By Product Type
By Application
By Country
GCC (By Product Type)
South Africa (By Product Type)
Rest of Middle East & Africa (By Product Type)
- 1. Introduction
- 1.1. Market Scope
- 1.2. Market Segmentation
- 1.3. Market Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 4. Key Insights
- 4.1. Prevalence of Key Disease Conditions –Key Regions/Country
- 4.2. New Product Launch
- 4.3. Pipeline Analysis
- 4.4. Impact of COVID-19 on the Immunomodulators Market
- 4.5. Key Industry Developments - Mergers, Acquisitions, and Partnerships
- 5. Global Immunomodulators Market Analysis, Insights and Forecast, 2016-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Product Type
- 5.2.1. Immunosuppressants
- 5.2.2. Immunostimulants
- 5.3. Market Analysis, Insights and Forecast – By Application
- 5.3.1. Respiratory
- 5.3.2. Oncology
- 5.3.3. Multiple Sclerosis
- 5.3.4. Others
- 5.4. Market Analysis, Insights and Forecast – By Geography
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa
- 6. North America Immunomodulators Market Analysis, Insights and Forecast, 2016-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Product Type
- 6.2.1. Immunosuppressants
- 6.2.2. Immunostimulants
- 6.3. Market Analysis, Insights and Forecast – By Application
- 6.3.1. Respiratory
- 6.3.2. Oncology
- 6.3.3. Multiple Sclerosis
- 6.3.4. Others
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.1.1. By Product Type
- 6.4.1.1.1. Immunosuppressants
- 6.4.1.1.2. Immunostimulants
- 6.4.2. Canada
- 6.4.2.1. By Product Type
- 6.4.2.1.1. Immunosuppressants
- 6.4.2.1.2. Immunostimulants
- 7. Europe Immunomodulators Market Analysis, Insights and Forecast, 2016-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Product Type
- 7.2.1. Immunosuppressants
- 7.2.2. Immunostimulants
- 7.3. Market Analysis, Insights and Forecast – By Application
- 7.3.1. Respiratory
- 7.3.2. Oncology
- 7.3.3. Multiple Sclerosis
- 7.3.4. Others
- 7.4. Market Analysis, Insights and Forecast – By Country/Sub-region
- 7.4.1. U.K.
- 7.4.1.1. By Product Type
- 7.4.1.1.1. Immunosuppressants
- 7.4.1.1.2. Immunostimulants
- 7.4.2. Germany
- 7.4.2.1. By Product Type
- 7.4.2.1.1. Immunosuppressants
- 7.4.2.1.2. Immunostimulants
- 7.4.3. France
- 7.4.3.1. By Product Type
- 7.4.3.1.1. Immunosuppressants
- 7.4.3.1.2. Immunostimulants
- 7.4.4. Spain
- 7.4.4.1. By Product Type
- 7.4.4.1.1. Immunosuppressants
- 7.4.4.1.2. Immunostimulants
- 7.4.5. Italy
- 7.4.5.1. By Product Type
- 7.4.5.1.1. Immunosuppressants
- 7.4.5.1.2. Immunostimulants
- 7.4.6. Scandinavia
- 7.4.6.1. By Product Type
- 7.4.6.1.1. Immunosuppressants
- 7.4.6.1.2. Immunostimulants
- 7.4.7. Rest of Europe
- 7.4.7.1. By Product Type
- 7.4.7.1.1. Immunosuppressants
- 7.4.7.1.2. Immunostimulants
- 8. Asia Pacific Immunomodulators Market Analysis, Insights and Forecast, 2016-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Product Type
- 8.2.1. Immunosuppressants
- 8.2.2. Immunostimulants
- 8.3. Market Analysis, Insights and Forecast – By Application
- 8.3.1. Respiratory
- 8.3.2. Oncology
- 8.3.3. Multiple Sclerosis
- 8.3.4. Others
- 8.4. Market Analysis, Insights and Forecast – By Country/Sub-region
- 8.4.1. Japan
- 8.4.1.1. By Product Type
- 8.4.1.1.1. Immunosuppressants
- 8.4.1.1.2. Immunostimulants
- 8.4.2. China
- 8.4.2.1. By Product Type
- 8.4.2.1.1. Immunosuppressants
- 8.4.2.1.2. Immunostimulants
- 8.4.3. India
- 8.4.3.1. By Product Type
- 8.4.3.1.1. Immunosuppressants
- 8.4.3.1.2. Immunostimulants
- 8.4.4. Australia
- 8.4.4.1. By Product Type
- 8.4.4.1.1. Immunosuppressants
- 8.4.4.1.2. Immunostimulants
- 8.4.5. Southeast Asia
- 8.4.5.1. By Product Type
- 8.4.5.1.1. Immunosuppressants
- 8.4.5.1.2. Immunostimulants
- 8.4.6. Rest of Asia Pacific
- 8.4.6.1. By Product Type
- 8.4.6.1.1. Immunosuppressants
- 8.4.6.1.2. Immunostimulants
- 9. Latin America Immunomodulators Market Analysis, Insights and Forecast, 2016-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Product Type
- 9.2.1. Immunosuppressants
- 9.2.2. Immunostimulants
- 9.3. Market Analysis, Insights and Forecast – By Application
- 9.3.1. Respiratory
- 9.3.2. Oncology
- 9.3.3. Multiple Sclerosis
- 9.3.4. Others
- 9.4. Market Analysis, Insights and Forecast – By Country/Sub-region
- 9.4.1. Brazil
- 9.4.1.1. By Product Type
- 9.4.1.1.1. Immunosuppressants
- 9.4.1.1.2. Immunostimulants
- 9.4.2. Mexico
- 9.4.2.1. By Product Type
- 9.4.2.1.1. Immunosuppressants
- 9.4.2.1.2. Immunostimulants
- 9.4.3. Rest of Latin America
- 9.4.3.1. By Product Type
- 9.4.3.1.1. Immunosuppressants
- 9.4.3.1.2. Immunostimulants
- 10. Middle East & Africa Immunomodulators Market Analysis, Insights and Forecast, 2016-2027
- 10.1. Key Findings / Summary
- 10.2. Market Analysis, Insights and Forecast – By Product Type
- 10.2.1. Immunosuppressants
- 10.2.2. Immunostimulants
- 10.3. Market Analysis, Insights and Forecast – By Application
- 10.3.1. Respiratory
- 10.3.2. Oncology
- 10.3.3. Multiple Sclerosis
- 10.3.4. Others
- 10.4. Market Analysis, Insights and Forecast – By Country/Sub-region
- 10.4.1. GCC
- 10.4.1.1. By Product Type
- 10.4.1.1.1. Immunosuppressants
- 10.4.1.1.2. Immunostimulants
- 10.4.2. South Africa
- 10.4.2.1. By Product Type
- 10.4.2.1.1. Immunosuppressants
- 10.4.2.1.2. Immunostimulants
- 10.4.3. Rest of Middle East & Africa
- 10.4.3.1. By Product Type
- 10.4.3.1.1. Immunosuppressants
- 10.4.3.1.2. Immunostimulants
- 11. Competitive Analysis
- 11.1. Key Industry Developments
- 11.2. Global Market Share Analysis (2019)
- 11.3. Company Profiles (Overview, Product Types & Services, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
- 11.3.1. F. Hoffmann-La Roche Ltd
- 11.3.1.1. Overview,
- 11.3.1.2. Product Types & Services,
- 11.3.1.3. SWOT Analysis,
- 11.3.1.4. Recent Developments,
- 11.3.1.5. Strategies,
- 11.3.1.6. Financials (Based on Availability)
- 11.3.2. Novartis AG
- 11.3.2.1. Overview,
- 11.3.2.2. Product Types & Services,
- 11.3.2.3. SWOT Analysis,
- 11.3.2.4. Recent Developments,
- 11.3.2.5. Strategies,
- 11.3.2.6. Financials (Based on Availability)
- 11.3.3. Biogen
- 11.3.3.1. Overview,
- 11.3.3.2. Product Types & Services,
- 11.3.3.3. SWOT Analysis,
- 11.3.3.4. Recent Developments,
- 11.3.3.5. Strategies,
- 11.3.3.6. Financials (Based on Availability)
- 11.3.4. Teva Pharmaceutical Industries Ltd.
- 11.3.4.1. Overview,
- 11.3.4.2. Product Types & Services,
- 11.3.4.3. SWOT Analysis,
- 11.3.4.4. Recent Developments,
- 11.3.4.5. Strategies,
- 11.3.4.6. Financials (Based on Availability)
- 11.3.5. Amgen, Inc
- 11.3.5.1. Overview,
- 11.3.5.2. Product Types & Services,
- 11.3.5.3. SWOT Analysis,
- 11.3.5.4. Recent Developments,
- 11.3.5.5. Strategies,
- 11.3.5.6. Financials (Based on Availability)
- 11.3.6. Bristol-Myers & Squibb Company
- 11.3.6.1. Overview,
- 11.3.6.2. Product Types & Services,
- 11.3.6.3. SWOT Analysis,
- 11.3.6.4. Recent Developments,
- 11.3.6.5. Strategies,
- 11.3.6.6. Financials (Based on Availability)
- 11.3.7. Merck Sharp & Dohme Corp.
- 11.3.7.1. Overview,
- 11.3.7.2. Product Types & Services,
- 11.3.7.3. SWOT Analysis,
- 11.3.7.4. Recent Developments,
- 11.3.7.5. Strategies,
- 11.3.7.6. Financials (Based on Availability)
- 11.3.8. Eli Lilly and Company
- 11.3.8.1. Overview,
- 11.3.8.2. Product Types & Services,
- 11.3.8.3. SWOT Analysis,
- 11.3.8.4. Recent Developments,
- 11.3.8.5. Strategies,
- 11.3.8.6. Financials (Based on Availability)
- 11.3.9. Other Prominent Players
- 11.3.9.1. Overview,
- 11.3.9.2. Product Types & Services,
- 11.3.9.3. SWOT Analysis,
- 11.3.9.4. Recent Developments,
- 11.3.9.5. Strategies,
- 11.3.9.6. Financials (Based on Availability)
- 12. Strategic Recommendations
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook